Fundz

Who to call at Amarna Therapeutics, and when

Fundz watches for the moments Amarna Therapeutics starts buying, and tells you who to reach.

  • An alert the day Amarna Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Amarna Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Amarna Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development

Dec 03, 2024

Contract Type

partnership

LeidenManufacturingBiotechnologyHealth CareScience And EngineeringBiopharma

Description

Amarna Therapeutics has announced a strategic collaboration with NorthX Biologics to advance the clinical trial manufacturing of Nimvec™ AM510, a groundbreaking gene therapy platform designed to transform the treatment of immune-mediated diseases. The partnership will start with the transfer of Amarna's research-scale production process for Nimvec™ AM510 to NorthX Biologics, initiating the Chemistry, Manufacturing, and Controls (CMC) development process at NorthX.

Company Information

Company

Amarna Therapeutics

Location

Leiden, South Holland, Netherlands

About

Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of rare and prevalent diseases. The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVero) that for the first time makes it possible to produce SV40-derived vectors suitable for therapeutic use. The company's fully integrated gene therapy platform combining SuperVero with its genetically engineered SVec viral vector is truly unique in its intrinsic capability to deliver transgenes without eliciting immune responses to the vector nor to the transgene product. Leveraging this 'natural' non-immunogenicity feature of its gene delivery system in humans, Amarna is developing a broad pipeline of safe effective and durable gene therapies focused on genetic disorders, autoimmune diseases and chronic inflammation. Founded in 2008, Amarna's head office is based in Leiden Bio Science Park, the Netherlands, with a research subsidiary located in Seville, Spain.

Related People

Henk
Likely contact at this company
••••••••@••••••••

See Henk's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Amarna Therapeutics's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Amarna Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.